Minerva Neurosciences (NERV) Reports Q2 Loss of $0.27/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St slightly higher as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- FedEx pilots ratify new collective bargaining agreement
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
August 3, 2017 7:31 AM EDTFDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half of 2017
Amended agreement with Janssen supports dual focus of clinical development with MIN-202 in insomnia and major depressive disorder
Extended financial runway allows for timely advancement of clinical development with multiple product candidates
WALTHAM, Mass., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical... More
